Clinical Trials Insights
Clinical Trials Insights
AbbVie announces positive topline results from the phase 3 trial showing Etentamig significantly improved response rate and progression-free survival in patients with relapsed/refractory multiple...
AbbVie has announced positive topline results from a phase 3 study evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT)...
Clinical Trials Insights
African Bundibugyo ebolavirus vaccine candidate advanced to clinical trials
Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness...
Clinical Trials Insights
NRG Therapeutics presents data on lead clinical asset NRG5051 confirming novel disease-modifying approach to ALS
NRG, an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today presented a poster on preclinical...
Clinical Trials Insights
VarmX enrols first participant in global phase 3 trial evaluating VMX‑C001 in urgent surgery
VarmX, a biotech company developing innovative approaches to bypass direct oral anticoagulants targeting activated factor Xa (FXa inhibitors), enrolled the first participant in its global phase 3...
Clinical Trials Insights
Novo Nordisk provides update on a phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordiskhas announced headline results from the cardiovascular outcomes from a phase 3 trial.
While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway,...
Clinical Trials Insights
Kodiak Sciences completes enrolment in first pivotal cohort in the phase 3 trial of KSI-101 for macular oedema secondary to inflammation and reaffirms topline...
Kodiak Sciences Inc. has completed enrolment of the first 300-patient cohort in its clinical trial, supporting pivotal analysis of the KSI-101 phase 3 programme...
Clinical Trials Insights
Ractigen Therapeutics announces completion of enrolment and first dosing in phase 2 clinical trial of RAG-17 for SOD1-ALS
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, has completed patient enrolment and initial dosing across all cohorts in its phase 2...
Clinical Trials Insights
BioVie announces topline results of phase 2 trial of bezisterim in early Parkinson’s disease
BioVie Inc., a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, has announced results from the phase 2 trial evaluating its...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
